Capsaicin-sensitive sensory nerve desensitization |
neonatal capsaicin treatment |
↓ |
neonatal capsaicin treatment, dilated cardiomyopathy (DCM) and control rat |
enhanced EPR compared to control |
detrimental |
[101] |
epicardial TRPV1 ablation by high dose RTX |
epicardial ↓ |
post-MI-induced HF with RTX treatment in rat |
improved cardiac compliance |
detrimental |
[105] |
intrathecal RTX treatment |
spinal cord ↓ |
transverse aortic constriction (TAC)-induced HF |
improved cardiac function |
detrimental |
[106] |
sc. capsaicin treatment for 3 days at increasing doses |
↓ |
sensory neuropathy-induced HFpEF |
impaired myocardial relaxation |
beneficial |
[103,104] |
Pharmacological or genetic modulation of the TRPV1 receptor |
genetic deletion |
↓ |
7 days post-MI mouse |
increased infarct size |
beneficial |
[108] |
genetic deletion and dietary capsaicin for 24 weeks |
↑ |
high-salt diet-induced cardiac hypertrophy, mouse |
improved mitochondrial function |
beneficial |
[111] |
TRPV1 gene disruption |
↓ |
TAC-induced HF |
reduced cardiac hypertrophy |
detrimental |
[113] |
genetic deletion |
↓ |
TAC-induced HF |
decreased cardiac function and increased TNFα and IL-6 |
beneficial |
[112] |
genetic deletion and dietary capsaicin for 10 weeks |
↑ |
TAC-induced HF |
attenuated hypertrophy in WT |
beneficial |
[114] |
TRPV1 activation by eugenol, capsazepine |
↑ |
acute doxorubicin cardiotoxicity |
improved cardiac function |
beneficial |
[117] |
SA13353 TRPV1 agonist, and capsazepine |
↑ |
doxorubicin-induced HF, ALDH2 transgene mouse |
improved cardiac function |
beneficial |
[116] |
genetic deletion, AMG-9810 TRPV1 antagonist |
↓ |
LPS-induced endotoxemia, mouse |
cardiac dysfunction |
beneficial |
[120] |